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Abstract
Background: Cardiotocography is almost ubiquitous in its use in intrapartum care. Although it has been
demonstrated that there is some benefit from continuous intrapartum fetal monitoring using cardiotocography,
there is also an increased risk of caesarean section which is accompanied by short-term and long-term risks to the
mother and child. There is considerable potential to reduce unnecessary operative delivery with up to a 60% false
positive diagnosis of fetal distress using cardiotocography alone. ST analysis of the fetal electrocardiogram is a
promising adjunct to cardiotocography alone, and permits detection of metabolic acidosis of the fetus, potentially
reducing false positive diagnosis of fetal distress.
Methods: This study will be a single-centre, parallel-group, randomised controlled trial, conducted over 3 years. The
primary hypothesis will be that the proportion of women with an emergency caesarean section on ST analysis will
not equal that for women on cardiotocography monitoring alone. Participants will be recruited at the Women’s
and Children’s Hospital, a high-risk specialty facility with approximately 5000 deliveries per annum. A total of 1818
women will be randomised to the treatment or conventional arm with an allocation ratio of 1:1, stratified by parity.
The primary outcome is emergency caesarean section (yes/no). Statistical analysis will follow standard methods for
randomised trials and will be performed on an intention-to-treat basis. Secondary maternal and neonatal outcomes
will also be analysed. Additional study outcomes include psychosocial outcomes, patient preferences and cost-
effectiveness.
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Discussion: Approximately 20% of Australian babies are delivered by emergency caesarean section. This will be the first
Australian trial to examine ST analysis of the fetal electrocardiogram as an adjunct to cardiotocography as a potential
method for reducing this proportion. The trial will be among the first to comprehensively examine ST analysis, taking into
account the impact on psychosocial well-being as well as cost-effectiveness. This research will provide Australian evidence
for clinical practice and guideline development as well as for policy-makers and consumers to make informed,
evidence-based choices about care in labour.
Trial registration: ANZCTR, ACTRN1261800006268. Registered on 19 January 2018.
Keywords: Continuous electronic fetal monitoring, Cardiotocography, ST analysis, Caesarean section, Randomised
controlled trial, START
Background
Use of cardiotocography (CTG) is almost ubiquitous in
intrapartum care [1]. In fact, continuous CTG is one of the
most common procedures undertaken during labour, with
routine data collection and other reports from Australia,
the setting for STan Australian Randomised controlled
Trial (START), showing that it is applied in 60–70% of all
labours [2, 3]. While systematic reviews demonstrate bene-
fit from such monitoring [4], important shortcomings exist,
notably in relation to risk of increased rates of caesarean
section [4, 5] which in turn can be accompanied by short-
term and long-term risks to the mother and child [6]. One-
third of Australian women now deliver via caesarean sec-
tion [7], with emergency caesarean section rates of between
18 and 20% [8]. While CTG is also associated with an in-
crease in instrumental vaginal birth when compared with
intermittent auscultation, it shows no improvement in
overall perinatal death rates or cerebral palsy rates [4].
A promising adjunct to CTG is electronic fetal moni-
toring which also incorporates ST analysis (STan) of the
fetal electrocardiogram. This approach permits detection
of metabolic acidosis of the fetus by identifying changes
to the ST segment of the unborn baby’s ECG [9] which
are correlated with a simultaneously performed CTG,
potentially reducing false positive diagnosis of fetal dis-
tress. With up to a 60% false positive diagnosis of fetal
distress using CTG alone [10], there is considerable po-
tential to reduce unnecessary operative delivery.
The main potential benefit for STan monitoring lies in
the associated reduction in use of scalp pH sampling in
low emergency caesarean section environments. While
the most recent Cochrane meta-analysis [11] found no
significant reduction in caesarean section rate in low
caesarean section environments, where arguably fewer
unnecessary caesarean sections are performed, a statisti-
cally significant reduction in the relative risk of women
having scalp pH samples was demonstrated. This finding
has subsequently been supported in an individual patient
data meta-analysis [12].
This has crucial implications for Australian practice,
as the indications for a decision for emergency caesarean
section are the same as those for deciding to undertake
scalp pH sampling. The specific relevance to our trial is
that scalp pH testing is variably used in Australia, as its
clinical utility has been seriously questioned [13]. How-
ever, it can be reasonably argued that if fetal blood sam-
pling was indicated in a European context, a caesarean
section would have been indicated in the Australian
context.
There are additional factors which suggest that the
European trials, as well as the recently published multi-
centre US study [14] which also showed no reduction in
caesarean section, have limited generalisability to Aus-
tralian practice. Firstly, the four European trials [15–18]
included in the Cochrane review [11], which included
women having STan for standard indications, had an
overall emergency caesarean section rate of 10.6%, in
contrast to the emergency caesarean section rate in
Australia of approximately 18–20% [8]. Given that
Australia has a higher rate of potentially avoidable cae-
sarean sections, this would enhance the degree to which
a reduction in such unnecessary caesarean section is
possible. Also, US fetal monitoring practice is funda-
mentally different to that in Australia. The US study [14]
included women at low risk for caesarean section who
would not be offered CTG monitoring in Australia, and
would have a low background risk of caesarean section
regardless of monitoring type.
Further, delivery decisions for observed STan events
were set at a lower threshold in the US study relative to
the European guidelines and the clinical protocol that
we report here [19]. Additionally, the use of STan in the
US study did not result in fewer caesarean sections in an
environment where the alternative to this intervention at
full dilatation (i.e. instrumental vaginal delivery) is much
less common. Instrumental vaginal delivery occurred in
only about 6% of cases in the US study [14], compared
to 14% at the study hospital for the current trial [20].
A ‘culture change’ may also be necessary for effective
implementation of STan [21]. A programme of continu-
ing education and feedback, involving all of the labour-
ward midwives and medical staff, is a strong feature of
Turnbull et al. Trials          (2019) 20:539 Page 2 of 10
institutions where STan has been successfully imple-
mented, such as in Norwegian clinical practice [22].
While an education programme was implemented at the
beginning of the US trial [14], STan monitoring was ap-
plied to an average of only 1.4 women per week in each
of the study hospitals, providing exceptionally limited
opportunities for development and maintenance of skills.
This scenario is exacerbated in an organisational culture
where changeover of doctors and midwives, and hence
loss of trained STan expertise due to clinical rotations,
would be common.
The most recent meta analyses at the time of this pub-
lication [23, 24] showed that the use of STan is associ-
ated with no difference in the risk of caesarean section
(RR 0.93; 95% CI 0.78–1.12) [23] or operative vaginal de-
liveries for fetal distress (RR 0.87; 95% CI 0.74–1.03)
[23] but did show a 36% reduction in metabolic acidosis
(OR 0.64; 95% CI 0.46–0.88) [23]. Thus, the concurrence
of a low background emergency caesarean section rate
(in the European trials) and the use of fetal monitoring
in a low-risk population (in the US trial), along with in-
frequent use and thus less experience and training of
clinical staff, suggests that a reduction in caesarean sec-
tion may be possible in an Australian setting. In fact, our
pilot trial of 162 women indicated a 21.2% emergency
caesarean section rate for the CTG group, and a 13.4%
emergency caesarean section rate for the STan group
[25]. The proposed study presents the ideal opportunity
to examine STan in an adequately powered randomised
controlled trial, the first of its kind in Australia and the
first comprehensive trial worldwide.
Methods
Hypotheses
We believe that STan monitoring (cardiotocographic
electronic fetal monitoring (CTG) plus analysis of the
ST segment of the fetal electrocardiogram) of labouring
women will result in a reduction in the proportion of
emergency caesarean sections when compared with
CTG monitoring alone, from 17% to 12%. The primary
hypothesis is that the proportion of emergency caesarean
sections for women on STan will not be equal to that
for women on CTG monitoring alone. The study will be
powered to detect an absolute difference of 5% with a
conservative two-sided alternative. Our secondary hy-
potheses are that: there will be similarity in neonatal and
maternal clinical outcomes in both treatment arms;
STan monitoring will result in improved psychosocial
outcomes; STan monitoring will be cost-effective com-
pared to CTG alone; and STan monitoring will be pre-
ferred by women and they will be willing to trade-off the
disadvantages, such as reduced mobility and the need
for a fetal scalp electrode (FSE), in order to obtain ad-
vantages such as reduced chance of caesarean section.
Trial design
This study will be a single-centre, parallel-group, rando-
mised controlled trial, conducted over 3 years. Figure 1
provides the study flow and Fig. 2 shows a version of the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) figure for the trial. Details of
the study methodology are outlined in the SPIRIT
checklist in Additional file 1. There will be an interven-
tion group (CTG + STan) and a conventional treatment
group (CTG).
Trial administration, study population and eligibility
criteria
The trial is administered by the University of Adelaide,
Adelaide, South Australia and the Women’s and Chil-
dren’s Hospital, Women’s and Children’s Health Net-
work, Adelaide, South Australia. A total of 1818 women
who have antepartum or intrapartum risk factors that
increase the risk of fetal compromise for which continu-
ous electronic fetal monitoring during labour is recom-
mended will be randomised for the study. Participants
will be recruited at the Women’s and Children’s Hos-
pital, a high-risk specialty facility with approximately
5000 deliveries per annum. Women are eligible for the
trial if they meet the following inclusion criteria: 18 years
or older; capable of informed consent; literate in English;
and singleton fetus in cephalic presentation. Women will
be excluded from participating if: they are less than 36
weeks gestation; they are planning a caesarean birth or
require a caesarean due to placenta previa or vasa previa;
they have contraindications for use of a fetal scalp elec-
trode; they do not require continuous electronic fetal
monitoring; they have participated in the study in a pre-
vious pregnancy; or there are known fetal structural or
functional cardiac conditions.
Sample size
Considering the results of our pilot study [25], current
hospital rates for emergency caesarean section and elec-
tronic fetal monitoring, and the results of previous re-
search [12], we powered the primary hypothesis on a
reduction of emergency caesarean section from 17% to
12%, (i.e. a 5% absolute difference), with 80% power and
a conservative two-sided α = 0.05. To detect this abso-
lute difference between the treatment groups, a total
sample size of 1634 women is required. After allowing
for a very conservative 10% dropout after consent and a
further 22% attrition after consent due to no clinical in-
dication for fetal monitoring in labour, and a possible
further 5% non-compliance in the STan + CTG arm,
consent would need to be gained from at least 2588
women. Given a recruitment period of about 2 years, we
estimated that it would be possible to consent 2588
women, of whom 1818 will be subsequently randomised.
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This sample size would also provide power to detect
clinically meaningful differences in the secondary out-
comes of interest.
This is achievable at the study hospital. Of 5000
women per year birthing at the Women’s and Chil-
dren’s Hospital, 12% have elective caesarean sections
and do not labour, and approximately 8% are born pre-
term, leaving 80% of women to labour at term (4000
women per year). Of these women, approximately 80%
have electronic fetal monitoring (3200 women per
year). The US study [14] reported a consent and ran-
domisation rate of 25.6%. Assuming a conservative
consent and randomisation rate of only 20% of the
over 9600 women thus eligible over a 3-year period,
1920 women would be consented and randomised.
Given the 1818 consented and randomised women re-
quired in our sample size calculation, this sample size
should be achievable.
Fig. 1 Trial flow chart. CTG cardiotocography, STan ST analysis
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Ethical aspects and data storage
The randomised controlled trial was approved by the
Women’s and Children’s Health Network’s Human Re-
search Ethics Committee (HREC/17/WCHN/14) and is
covered by indemnity insurance. Original consent forms
will be stored in a locked filing cabinet, in a locked
room. Data will be stored on secure servers at the Uni-
versity of Adelaide and the Women’s and Children’s
Hospital. Data and consents will be retained for 15 years
after the publication of the trial according to the stan-
dards required by the Australian Code for the Respon-
sible Conduct of Research [26].
Study schedule
Women will be approached to ascertain interest in and
to seek consent about the study at 32–36 weeks gesta-
tion. Consent will be obtained by appropriately trained
clinicians and will take place at various locations
throughout the hospital including the labour ward, the
Women’s Assessment Service, antenatal/gynaecology
wards and antenatal outpatient clinics. After ongoing as-
sessment of eligibility during labour, eligible consenting
women will be randomised once the decision to elec-
tronically monitor the fetus during labour is made. Any
excluded or voluntarily withdrawn patients will receive
Fig. 2 The schedule of enrolment, interventions and assessments. CTG cardiotocography, ICU intensive care unit, STan ST analysis
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usual care without prejudice. Demographic and clinical
baseline data will be collected by the research midwife at
or soon after trial entry. Clinical observation will com-
mence at randomisation and will end 6 weeks postna-
tally. The last contact for most women will be at
approximately 7 weeks post delivery with the receipt of a
psychosocial questionnaire. A subset of women consent-
ing to additional follow-up will be contacted for a face-
to-face interview after the questionnaire has been
returned and a sub-sample of consecutive women will
also be asked to complete a second questionnaire at
about 16 weeks post delivery to understand patient pref-
erences using a Discrete Choice Experiment (DCE) sur-
vey (see Fig. 2).
Randomisation and blinding
Once consent is obtained and eligibility criteria are met,
participants will be randomised to either the treatment
group (CTG+ STan) or the conventional group (CTG only).
Simple randomisation with stratification for parity will be
implemented to produce a pre-determined schedule with an
allocation ratio of 1:1, with treatment allocations accessed
by a telephone-based system provided by NHMRC Clinical
Trials Centre at the University of Sydney.
Description of treatment arms
Continuous electronic fetal monitoring will be con-
ducted by midwives and obstetricians who have been
trained in the use of CTG and STan monitoring (holding
Australian national Fetal Surveillance Education Pro-
gram (FSEP) CTG accreditation, as well as in-house, in-
stitutional accreditation for competency at STan use and
interpretation). Within 6 weeks of birth, all labours and
deliveries will be reviewed by a multidisciplinary panel
of experienced clinicians to assess adherence to elec-
tronic fetal monitoring (CTG and STan) protocols and
procedures. Any evidence of protocol and STan guide-
line violations will be fed back to the relevant providers
to optimise protocol adherence.
Treatment arm (CTG + STan)
A STan-capable monitor (Neoventa) will be connected
to a tocodynometer on a belt applied to the woman’s
waist. If her membranes have been ruptured, a FSE will
be applied to the occiput of the fetal scalp, and STan
monitoring will commence and be interpreted according
to the STAN guidelines [27]. If membranes are still in-
tact, they will be artificially ruptured when it is safe and
clinically appropriate. A FSE will then be applied, and
STan monitoring commenced. If it is not possible or
clinically appropriate to rupture the membranes, moni-
toring via a belt-mounted Doppler monitor will be com-
menced (as per clinical necessity, using the guidelines of
the Royal Australian and New Zealand College of
Obstetrics and Gynaecology (RANZCOG) guidelines
[28]). Once clinically appropriate and safe, the mem-
branes will be ruptured, a FSE will be applied and STan
monitoring will commence.
Conventional arm (CTG only)
A CTG machine (Philips or Neoventa) in the delivery room
will be activated. A belt with a tocodynometer will be ap-
plied to the woman’s waist. External monitoring of the fetal
heart rate will commence by a belt-mounted Doppler
monitor around her waist or, if clinically indicated, a FSE
will be applied to the fetal scalp and monitoring will com-
mence according to the RANZCOG guidelines [28].
Data collection
Maternal and neonatal data will be collected from retro-
spective case-note review by the research midwife who is
not involved in the primary provision of care. The treat-
ment allocation cannot be concealed because the con-
tent of the notes will reveal the care received. An
independent review of 20 records will be completed to
validate the quality and accuracy of data entry. Out-
comes and timepoints of data collection are detailed in
Fig. 2. Prospectively collected data will also be obtained
in order to construct a CONSORT flow chart [29, 30].
Primary outcome
The primary outcome is emergency caesarean section
(yes/no).
Secondary outcomes
Maternal secondary outcomes include the following:
type of labour; indication for induction; type of fetal
monitoring received; cardio-monitoring method; number
and classification of CTG abnormalities and clinician re-
sponses; number and type of ST events and clinician re-
sponses; adherence to STAN guidelines; use of and
result for scalp pH and/or lactate; use of oxytocin infu-
sion and length of use; complications of labour; length
of labour; use of pharmacologic analgesia and non-
pharmacologic pain relief; mode of delivery; declared
reason if caesarean section and Robson classification;
trial of assisted vaginal delivery resulting in caesarean
section; postpartum antibiotic use, endometritis and ma-
ternal readmission; maternal ICU admission; maternal
death; and length of stay.
Neonatal secondary outcomes include the following:
intrapartum fetal death; birth weight; gender; intubation
or external cardiac massage at delivery; arterial and venous
cord gases (pH, lactate, base excess); APGAR score at 1, 5
and 10min; limb or clavicular fracture; neonatal death;
seizure(s); BRAINZ monitoring; presence and grade of
neonatal encephalopathy; requirement for cooling; proven
infection; antibiotic usage; potential complication from
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use of fetal scalp electrode; scalp trauma; admission to
neonatal intensive care, special care or qualified on ward;
length of stay; jaundice requiring phototherapy; respira-
tory distress; meconium aspiration syndrome; major con-
genital malformation; other major complications; and
neonatal readmission.
Additional study outcomes
All participants in the study are offered the opportunity to
participate in research observing psychosocial outcomes
of the monitoring they received, and a sub-sample of con-
secutive participants will also be offered the opportunity
to participate in research regarding preferences, utilising a
DCE survey. In consenting to participate in the rando-
mised controlled trial, participants also agree to being sent
questionnaires during the postnatal period.
Women are invited to complete a psychosocial ques-
tionnaire which they will receive approximately 7 weeks
after delivery, with the exception of women with severe
adverse outcomes (e.g. fetal or neonatal death). The
questionnaire has been constructed using several mea-
sures to examine satisfaction with continuous electronic
fetal monitoring, birth satisfaction, general health, post-
natal depression and infant feeding practices. These
tools have robust psychometric properties and have been
successfully applied in the maternity setting in past stud-
ies. The tools include the EQ-5D [31], the General
Health Questionnaire [32], the Edinburgh Postnatal De-
pression Scale (EPDS) [33], a measure of infant feeding
[34] and the Birth Satisfaction Scale—Revised (BSS-R)
[35]. Also included are demographic questions, a purpose-
designed scale of monitoring satisfaction, trade-off ques-
tions and open-ended questions on positive and negative
experiences. A subset of women who return the question-
naire, and indicated they are interested in participating, will
be contacted regarding a face-to-face interview in relation
to their satisfaction and experience with the continuous
electronic fetal monitoring they received.
Women may also be invited to participate in a patient
preference survey using a DCE which will examine what
trade-offs women are likely to make in order to obtain
advantages such as reduced change of emergency caesar-
ean section. A three-stage approach, previously success-
fully applied [36], will be followed: existing data from a
qualitative study [37] conducted during the pilot study
will be used to determine the key factors (attributes) in-
fluencing preference; a preliminary questionnaire will be
developed and piloted, providing data to inform an effi-
cient experimental design for the main survey; and the
final DCE questionnaire will be sent to women at ap-
proximately 16 weeks postnatal.
Lastly, a cost-effectiveness study will be completed at
the end of the randomised controlled trial. Taking a hos-
pital perspective, and utilising cost data generated by
hospital systems from all participants in the study, the
incremental cost per emergency caesarean section
avoided will be calculated.
Statistical analysis
Analysis of the randomised controlled trial will be per-
formed by the Data, Design, Statistics and Research IT
Service of Adelaide Health Technology Assessment
(AHTA), School of Public Health, The University of Adel-
aide. Statistical analysis will follow standard methods for
randomised trials and will be performed on an intention-
to-treat basis, according to treatment allocation at ran-
domisation. All analyses will follow a pre-specified statis-
tical analysis plan. For dichotomous outcomes including
the primary outcome of caesarean section (yes/no), pro-
portions will be compared between treatment groups
using the relative risk with 95% CI, obtained from a log bi-
nomial regression analysis with adjustment for strata (de-
fined by parity) used in the randomisation. Further log
binomial regression analyses (for sensitivity) will examine
the effect of adjustment for parity, as well as pre-specified
prognostic baseline variables and/or variables not bal-
anced (by chance) at baseline, with results reported as the
relative risk with corresponding 95% CIs. Categorical out-
comes with more than two categories will be modelled
with multinomial or ordinal logistic regression (or an ap-
propriate generalised linear model alternative) with adjust-
ment for parity. Proportions will be compared between
treatment groups with relative risks and 95% CIs where
possible. Continuous outcomes will be compared using
differences between mean values estimated from linear or
generalised linear regressions (depending on the nature of
the data) adjusted for parity (with 95% CIs). Secondary
analyses will explore evidence for heterogeneity of effects
between the two parity strata using interaction tests and
subgroup analyses. All subgroup comparisons will be pre-
specified and performed with appropriate tests of inter-
action. Although this study will be underpowered to de-
termine equivalence of neonatal outcomes or maternal
secondary outcomes, the neonatal data will be able to be
incorporated into meta-analyses including neonatal data
from previous clinical trials (including the use of individ-
ual patient data).
For the psychosocial survey, analysis of the data will
be blinded to the specific treatment group, with simple
indicators ‘A’ and ‘B’ provided by AHTA.
For the DCE, analysis will begin using multinomial
logit (MNL) models and mixed logit models; alternative
model specifications (e.g. latent class models) may also
be used to explore preference heterogeneity. Models will
be evaluated for goodness of fit using the likelihood-ratio
χ2 statistic for the global test of zero model coefficients,
McFadden’s pseudo R2 and Akaike’s information criter-
ion (AIC). MNL and mixed logit model results will be
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presented as β parameters and odds ratios with 95%
confidence intervals. Trade-offs between parameters (e.g.
benefit–harm trade-offs) will also be estimated; and will
be calculated as the ratio of model parameters.
For the cost-effectiveness study, data collected from
clinical feeder systems at the hospital will be calculated
on a full absorption basis including labour and postnatal
ward, medical and midwifery staff, pathology, pharmacy,
operating theatre, medical and surgical supplies, goods
and services. Preparation of costing data will conform to
Australian Hospital Patient Costing Standards [38]. Dir-
ect cost comparisons will use case-mix classifications
(Australian Related Diagnosis Groups classification, ver-
sion 8.0) [39]. The incremental cost per emergency cae-
sarean section avoided will be calculated. Bootstrapping
will estimate a distribution around incremental costs
and incremental health outcomes, and confidence limits
around the incremental cost-effectiveness ratio will be
estimated. One-way sensitivity analysis will be conducted
around key variables, and a probabilistic sensitivity ana-
lysis will be conducted to estimate joint uncertainty in
all parameters.
Data safety and adverse event monitoring and reporting
Adverse events will be monitored for by the clinical in-
vestigators and research midwife at ward rounds or peri-
natal review sessions. The research midwife will also
monitor for adverse events as she extracts clinical data
from the case notes. Adverse events entered into the
data management software will automatically trigger the
generation of an email alert to the obstetrician and
paediatrician investigators. Additionally, results of the
EPDS within the psychosocial questionnaire will be
monitored to ascertain offers of referral.
A Data Safety Monitoring Committee (DSMC) has been
formed to assess emerging external evidence in relation to
STan, and to monitor adverse events, compliance with trial
protocol and progress of recruitment. The DSMC will be
notified of and meet as soon as possible after the occur-
rence of any of the following adverse events: maternal
death; and fetal or neonatal death that could be reasonably
attributed to, or partly caused by, CTG+ STan or CTG
alone. The DSMC will also be notified of and asked to de-
liberate on adverse events including unplanned intensive
care admissions (maternal or neonatal) and any other ad-
verse event of significant concern to the investigators or
clinical staff. The committee will also be convened in the
event that the chief investigator (CW) receives a report of
an adverse event, due to STan monitoring, from weekly
alerts of the published literature. Responses of the DSMC
may include cessation of the study or modification of the
protocol, which will in turn be re-submitted to the ethics
committees.
Dissemination of results
Results will be disseminated via peer-reviewed publica-
tions as well as at institutional and state-based clinical
meetings and national and international conferences
such as the Perinatal Society of Australia and New Zea-
land and the Royal College of Obstetrics and Gynaecol-
ogy. It is expected that the study will also be the subject
of journal clubs and Twitter feeds, and we will ensure
that the results are translated into relevant clinical
guidelines, practice and policy briefs, news releases, edu-
cational sessions and one-to-one briefings. Results will
also be directly disseminated via the Women’s Health-
care Australasia Clinical Network.
Discussion
About 20% of Australian babies are delivered via emer-
gency caesarean section [8]. At 35% overall, Australian
caesarean section rates continue to remain above the
OECD average (34% in 2014) and are among the highest
in the world, ranking 24th out of 31 OECD countries
(rates ranked lowest to highest) [40]. This will be the
first Australian trial to examine the potential for STan
technology to reduce this rate. It will also be among the
first to consider a more comprehensive examination of
STan, taking into account both the impact on broader
psychosocial well-being and patient preference, as well
as cost-effectiveness. Professional bodies such as the
Royal Australian and New Zealand College of Obstetrics
and Gynaecology are currently relying on international
evidence which our critique demonstrates is not general-
isable to Australian practice.
In previous trials, very little attention has been paid to
the views of women, midwives and obstetricians. This
may partly explain the problems experienced with up-
take in some settings [41]. In order to identify associated
psychosocial and organisational issues, we have already
conducted qualitative research with women throughout
the hospital [37] as well as obtaining the views of mid-
wives and obstetricians about the introduction of STan
and the accompanying educational programme [42]. In-
depth, semi-structured interviews incorporating hypo-
thetical written scenarios of STan and CTG revealed
that women’s views about monitoring are multifaceted
and likely to be influenced by perceptions related to four
key factors: risk in labour; mobility in labour; autonomy
and choice in labour; and trust in maternity providers
[37]. In contrast, doctors and midwives indicated four im-
portant areas for consideration when introducing STan: a
philosophy of care; the implementation process (including
training and education); the existence of research evi-
dence; and attitudes towards new technology [42].
This research will provide Australian evidence for clin-
ical practice and guideline development which is crucial
for policy-makers and consumers to make informed,
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evidence-based choices about care in labour. Given the
ubiquitous application of CTG monitoring, we also an-
ticipate that the trial will initiate and inform professional
discussions about monitoring at an international level.
Trial status
The trial is currently recruiting participants. Current proto-
col version 28 (13 March 2019). Recruitment commenced
in 22 January 2018; expected recruitment completion is July
2020. The primary investigator will notify the trial register,
the ethics committees, the DSMC and this journal should
any major changes be made to the trial protocol.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents (PDF 116 kb)
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